Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Surf oncology paying VCNX for its technology
Guess who has a big stake in Surf?.
non other than Cathie Wood from Ark investment which ran Tsla from $50 to $700 plus
Great endorsement for VCNX
Found this stock on Friday and bought a little today. Like what I see here. Think is has excellent upside
* * $VCNX Video Chart 02-19-2021 * *
Link to Video - click here to watch the technical chart video
This stock is a total deal at these levels. Looking at the chart it has all the support in the world at $2 and little to resistance beyond $3.50. The bad news has already past and the director just upped his options and stock allocations and acquisitions. Near term target $3.5-$5 low end $6.5-17 high end. IMO
Thanks for the trip to the ATM. I will probably be back in the near future for another ride.
Price action and support is next level. I say we see $3.5-$9.00 very soon imo. This next rip will be huge
I can’t believe how cheap this stock is. I love when these $5-10 stocks get slammed. The low volume and stabile bottomed chart makes this prime for a hard move up. I dream of a buy out from Bristol or a Keytruda deal. Long on this to $5 at least. Near term target $3-8. IMO
What is the catalyst for the rip?
Ok what is it?
I like fundamentals
VCNX.....As the old adage says, "Reading is fundamental".
https://finance.yahoo.com/quote/VCNX/profile?p=VCNX
GO VNCX
"PEACE"
$VCNX actually it was their only product as bagholders and bottom feeders chase a falling machete with major dilution ahead as they have little to no cash.
VCNX's missed end point for pepinemab treatment for Huntington's disease hit the SP pretty hard indeed. However, let us not forget that is not the only product, a cooking, in the oven.
Vaccinex, Inc.
Profile and Description
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), Huntington's disease, osteosarcoma, melanoma, and Alzheimer's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; and VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
https://finance.yahoo.com/quote/VCNX/profile?p=VCNX
GO VCNX
"PEACE"
CNN MONEY Business forecasts https://money.cnn.com/quote/forecast/forecast.html?symb=VCNX
We will see....
GO VCNX
"PEACE"
Expecting a huge pop from oversold territory Monday after ASCO results of Huntington Top Line projections. Could see $12-14 IMO
Big news will easily send this to 14+ Secure the bag.
* * $VCNX Video Chart 07-14-2020 * *
Link to Video - click here to watch the technical chart video
$VCNX: Vaccine player on a roll........... GOING UP !!!!!!
Another one the button
GO $VCNX
Trading float is 3M shares. VCNX
Additional Alzheimer's Drug Discovery Foundation awards may be heading to VCNX.
Vaccinex Announces $3 Million Award from the Alzheimer's Drug Discovery Foundation
8:02 am ET December 10, 2019 (Globe Newswire) Print
Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel antibody therapies in neurodegenerative diseases and cancer, today announced that it has been granted an award, in the form of an investment of up to approximately $3 million, from the Alzheimer's Drug Discovery Foundation (ADDF) to evaluate its lead drug candidate, pepinemab (VX15/2503), in Alzheimer's Disease (AD). The mission of the ADDF is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.
"This is the second award from a major Alzheimer's research foundation to be announced recently in support of this study in Alzheimer's disease," said Maurice Zauderer, President & CEO, Vaccinex, Inc. "Last month, we announced a $750,000 grant from the Alzheimer's Association for this same program. Alzheimer's is a devastating disease with no effective treatment, and we are very encouraged by the broad support for our novel strategy to treat this disease. This is an important Vaccinex program that together with our large, ongoing, potentially pivotal SIGNAL study in Huntington's disease and our collaboration with Merck KGaA in Non-Small Cell Lung Cancer could bring important benefits to our patients and reward our dedicated employees and investors."
Eric Siemers, MD, formerly senior medical director of the Alzheimer's Disease Global Development Team at Eli Lilly and Company, will serve as a principal investigator of this new 60 patient, randomized, placebo-controlled, multi-center phase 1 clinical study, which is expected to enroll the first patient in the second quarter of 2020. Top-line data is anticipated in late 2021 or early 2022.
Vaccinex's plan for this study is based on evidence from Cohort A of its "SIGNAL" clinical trial in Huntington's disease (HD) that showed treatment with pepinemab induces a sharp increase in glucose metabolism in the brain during HD disease progression as detected by conventional FDG-PET imaging. Previous studies in Alzheimer's disease have shown that decline in glucose metabolism correlates with cognitive decline. Recently, it has been reported that FDG-PET is superior to AB amyloid-PET as an indicator of cognitive decline in early Alzheimer's disease.
Dr. Siemers said, "While treatment options exist to address many of the symptoms of Alzheimer's disease, we have yet to develop an effective treatment to slow or prevent disease progression. Pepinemab's unique mechanism of action has shown encouraging effects on FDG-PET signal in Huntington's Disease patients, and these results provide a strong rationale to expand treatment to Alzheimer's Disease. I am eager to work with the Vaccinex team to initiate this development program as quickly as possible."
The award from ADDF will be in the form of an equity investment to be paid in two installments, $2 million of which is subject to an IRB approval that is expected by January 2020, with the remaining $992,766 to be paid subject to the achievement of an enrollment milestone. The Company will issue common stock to ADDF at the then current market price.
"Alzheimer's disease is a complex neurodegenerative disease, and many studies now point to the involvement of neuroinflammation in its progression," said Dr. Howard Fillit, founding executive director and chief science officer of the ADDF. "The ADDF is pleased to help advance Vaccinex's research program to test this drug candidate in Alzheimer's patients in a phase 2a clinical trial."
About SIGNAL
SIGNAL is a multi-center, double-blind, placebo-controlled study of pepinemab as a potential treatment for people with Huntington's disease, a devastating neurodegenerative disease. Based on data from SIGNAL Cohort A, pepinemab (VX15/2503) treatment resulted in a sharp increase in FDG-PET signal, in comparison to the decrease observed in the placebo group. SIGNAL Cohort B1 has enrolled 179 subjects with manifest disease for 18 months of treatment and SIGNAL Cohort B2 has enrolled 86 late prodromal subjects for 18 to 36 months of treatment. Primary completion of the studies is anticipated in July 2020, with topline data expected in the second half of 2020.
About Alzheimer's Drug Discovery Foundation
Founded in 1998 by Leonard A. Lauder and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has granted more than $130 million to fund over 600 programs for Alzheimer's and related dementias in academic centers and biotechnology companies in 19 countries. To learn more, visit: http://www.alzdiscovery.org/.
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington's disease. Vaccinex is based in Rochester, New York.
VCNX INVESTMENT HIGHLIGHTS:
*Recent $40 million Initial Public Offering led by: Oppenheimer, Ladenburg and BTIG
*Lead Program(VX15) is humanized monoclonal antibody that binds to and blocks unique target - Semaphorin 4D(SEMA4D)
*1st Lead trial(Phase II) will have a readout at ASCO in June(NSCLC trial) after enrollment complete in May 2019 - partner Merck KGaA
*2nd Combo Phase 1/2 melanoma Trial in combo with nivolumab - partnership with Bristol Myers Squibb
*Anti-SEMA4D Antibody enhances Activity of Immune Checkpoint Inhibitors
*Huntington's Disease(HD) - neurodegenerative disease caused by mutation in a single gene - symptoms appear between ages 30 to 50
*No currently approved treatments to alter the course of Huntington's Disease - Vaccinex program granted Orphan Drug and Fast Track by FDA
*Very experienced Management team and Board of Directors
Vaccinex - Company Background:
Vaccinex, Inc. (Nasdaq: VCNX) is a publicly-traded clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases with unmet medical needs, including neurodegenerative diseases, cancer and autoimmune disorders.
Market Capitalization: $75 million
Range - 52 week: $12.00 - $3.32
Current Price: $5.50
Trades on: Nasdaq NASDAQ
Ticker Symbol: VCNX
Website: www.vaccinex.com
2nd time we were the first poster!
Is that a good sign or a bad sign lmao. Only time will tell. The other was CTEK. An entirely different animal, but equally ignored.
Adding Vaccinex (VCNX) $5.50, to Watch List After Investor Presentation.
http://internetstockreview.com/adding-vaccinex-vcnx-5-50-to-watch-list-after-investor-presentation/
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
176
|
Created
|
12/27/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |